ADAP
Price
$0.27
Change
-$0.01 (-3.57%)
Updated
Jul 10 closing price
Capitalization
73.1M
26 days until earnings call
NTLA
Price
$12.16
Change
+$0.03 (+0.25%)
Updated
Jul 10 closing price
Capitalization
1.26B
20 days until earnings call
Interact to see
Advertisement

ADAP vs NTLA

Header iconADAP vs NTLA Comparison
Open Charts ADAP vs NTLABanner chart's image
Adaptimmune Therapeutics
Price$0.27
Change-$0.01 (-3.57%)
Volume$520.16K
Capitalization73.1M
Intellia Therapeutics
Price$12.16
Change+$0.03 (+0.25%)
Volume$4.24M
Capitalization1.26B
ADAP vs NTLA Comparison Chart in %
Loading...
ADAP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ADAP vs. NTLA commentary
Jul 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADAP is a Buy and NTLA is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 11, 2025
Stock price -- (ADAP: $0.27 vs. NTLA: $12.16)
Brand notoriety: ADAP and NTLA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ADAP: 49% vs. NTLA: 83%
Market capitalization -- ADAP: $73.1M vs. NTLA: $1.26B
ADAP [@Biotechnology] is valued at $73.1M. NTLA’s [@Biotechnology] market capitalization is $1.26B. The market cap for tickers in the [@Biotechnology] industry ranges from $314.48B to $0. The average market capitalization across the [@Biotechnology] industry is $2.43B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ADAP’s FA Score shows that 0 FA rating(s) are green whileNTLA’s FA Score has 1 green FA rating(s).

  • ADAP’s FA Score: 0 green, 5 red.
  • NTLA’s FA Score: 1 green, 4 red.
According to our system of comparison, NTLA is a better buy in the long-term than ADAP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ADAP’s TA Score shows that 5 TA indicator(s) are bullish while NTLA’s TA Score has 6 bullish TA indicator(s).

  • ADAP’s TA Score: 5 bullish, 5 bearish.
  • NTLA’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, NTLA is a better buy in the short-term than ADAP.

Price Growth

ADAP (@Biotechnology) experienced а +9.72% price change this week, while NTLA (@Biotechnology) price change was +13.22% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +10.19%. For the same industry, the average monthly price growth was +16.32%, and the average quarterly price growth was +20.67%.

Reported Earning Dates

ADAP is expected to report earnings on Nov 05, 2025.

NTLA is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+10.19% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NTLA($1.26B) has a higher market cap than ADAP($73.1M). NTLA YTD gains are higher at: 4.288 vs. ADAP (-49.081). ADAP has higher annual earnings (EBITDA): -50.18M vs. NTLA (-530.8M). NTLA has more cash in the bank: 504M vs. ADAP (59.6M). ADAP has less debt than NTLA: ADAP (48.7M) vs NTLA (119M). ADAP has higher revenues than NTLA: ADAP (180M) vs NTLA (45.6M).
ADAPNTLAADAP / NTLA
Capitalization73.1M1.26B6%
EBITDA-50.18M-530.8M9%
Gain YTD-49.0814.288-1,145%
P/E RatioN/AN/A-
Revenue180M45.6M395%
Total Cash59.6M504M12%
Total Debt48.7M119M41%
FUNDAMENTALS RATINGS
ADAP vs NTLA: Fundamental Ratings
ADAP
NTLA
OUTLOOK RATING
1..100
320
VALUATION
overvalued / fair valued / undervalued
1..100
51
Fair valued
30
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9797
PRICE GROWTH RATING
1..100
6437
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (30) in the Biotechnology industry is in the same range as ADAP (51). This means that NTLA’s stock grew similarly to ADAP’s over the last 12 months.

NTLA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ADAP (100). This means that NTLA’s stock grew similarly to ADAP’s over the last 12 months.

NTLA's SMR Rating (97) in the Biotechnology industry is in the same range as ADAP (97). This means that NTLA’s stock grew similarly to ADAP’s over the last 12 months.

NTLA's Price Growth Rating (37) in the Biotechnology industry is in the same range as ADAP (64). This means that NTLA’s stock grew similarly to ADAP’s over the last 12 months.

NTLA's P/E Growth Rating (100) in the Biotechnology industry is in the same range as ADAP (100). This means that NTLA’s stock grew similarly to ADAP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ADAPNTLA
RSI
ODDS (%)
Bullish Trend 1 day ago
86%
Bearish Trend 1 day ago
89%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
87%
MACD
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
86%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
79%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
80%
Advances
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 1 day ago
77%
Declines
ODDS (%)
Bearish Trend 10 days ago
90%
Bearish Trend 11 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
ADAP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CVLEX14.850.09
+0.61%
Cullen Value Retail
SWHFX23.58N/A
N/A
Schwab Health Care
FDGTX23.23N/A
N/A
Fidelity Advisor Dividend Growth M
FIONX16.54N/A
N/A
Fidelity SAI International Index
FIFNX24.80N/A
N/A
Fidelity Advisor Founders